John M. Kane, MD

JCP
Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia
Consensus Statement

November 28, 2022

This easy-to-use scale developed by 7 experts measures the impact of TD on patients’ daily functioning.
, , , et al
JCP
Reasons for Switching Antipsychotic Treatments
Original Research

September 5, 2022

Based on prescription records and prescriber notes, almost half of antipsychotic switches were due to side effects, and women were especially likely to be switched due to intolerability or...
, , , et al
JCP
ASCP Corner

November 30, 2021

This ASCP Corner article discusses how to identify treatment-resistant patients who would benefit from clozapine and then offers tips on how to start the treatment conversation with these patients.
,
JCP
Academic Highlights

May 4, 2021

What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical...
,
JCP
Educational Activity

March 23, 2021

Patients may be more willing to accept some adverse effects than others. Dr Kane offers advice on addressing side effects that prevent patients from maintaining their medication adherence.
JCP
Review Article

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
, , , et al
JCP
Letter to the Editor

June 16, 2020

Drs Kane and Correll reply to the letter "Depression as a Factor in Nonadherence in Schizophrenia" by Hirakawa and Ishii.
,
JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Academic Highlights

September 17, 2019

Long-acting injectable antipsychotics can be a powerful strategy in helping patients to receive ongoing benefit from treatment. You might think that you have adequately explained this treatment option to...
,
JCP
Original Research

April 23, 2019

Read a study examining if patients in the early phase of schizophrenia would accept LAI antipsychotic treatment.
, , , et al
JCP
Commentary

March 5, 2019

Read expert commentary on guidelines for treatment-resistant schizophrenia (TRS) to make more informed treatment decisions.
, , , et al
JCP
Original Research

December 18, 2018

Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe